VYNE Therapeutics (VYNE) FCF Margin Growth (3y) (2020 - 2026)
VYNE Therapeutics (VYNE) FCF Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15,064.00 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 723.00 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -1,409.00 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 73,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73,265.00 |
| Jun 30, 2025 | -431,122.00 |
| Mar 31, 2025 | -65,241.00 |
| Dec 31, 2024 | -703,484.00 |
| Sep 30, 2024 | 589,927.00 |
| Jun 30, 2024 | 106,701.00 |
| Mar 31, 2024 | -269,970.00 |
| Dec 31, 2023 | -616,717.00 |
| Sep 30, 2023 | -379,623.00 |
| Jun 30, 2023 | -926,659.00 |
| Mar 31, 2023 | -249,211.00 |
| Dec 31, 2022 | 58,072.00 |
| Mar 31, 2022 | 36,996.00 |
| Dec 31, 2021 | -427,570.00 |
| Jun 30, 2021 | -522,305.00 |
| Mar 31, 2021 | -301,028.00 |
| Dec 31, 2020 | -22,603.00 |
| Sep 30, 2020 | 65,405.00 |
| Jun 30, 2020 | -31,565.00 |
| Mar 31, 2020 | -175,693.00 |